CCT245737 (SRA737, PNT-737, SRA-737, PNT737, CCT-245737)是一种可口服的Chk1选择性抑制剂，IC₅₀值为1.3 nM，作用于Chk2的IC₅₀是2440 nM。CHK1是一种丝氨酸/苏氨酸激酶，分别通过改变CDC25A稳定性和CDC25C定位参与G1和G2检查点。

参考文献

1.Osborne JD, et al. Multiparameter Lead Optimization to Give an Oral Checkpoint Kinase 1 (CHK1) Inhibitor Clinical Candidate: (R)-5-((4-((Morpholin-2-ylmethyl)amino)-5-(trifluoromethyl)pyridin-2-yl)amino)pyrazine-2-carbonitrile (CCT245737). J Med Chem. 2016 Jun 9;59(11):5221-37.

2.Walton MI, et al. The clinical development candidate CCT245737 is an orally active CHK1 inhibitor with preclinical activity in RAS mutant NSCLC and Eμ-MYC driven B-cell lymphoma. Oncotarget. 2016 Jan 19;7(3):2329-42.

冰袋运输。粉末直接保存于-20℃，有效期3年。建议分装后-20℃干燥保存，避免反复冻融。